Addiction to psychoactive substances, such as alcohol and illegal narcotics, is referred to as substance abuse. Alcohol, prescription pharmaceuticals, and other legal substances can also be used excessively or improperly, which is what is meant by substance abuse. It refers to the risky use of psychoactive substances that can lead to dependence syndrome, a collection of behavioural, cognitive, and physiological phenomena that typically emerges after repeated substance use and that include a strong desire to take the drug, difficulties in controlling its use, prioritising drug use over other activities and obligations, increased tolerance, and occasionally a physical withdrawal state. It is important to note that substance abuse differs from addiction in that people with substance abuse difficulties may stop using drugs or modify their destructive behaviour, but people with addiction cannot stop using drugs or chemicals even after they cause harm. In actuality, addiction is a sickness. Some people can start abusing substances when they are children or teenagers, while others may start using and abusing substances as adults. There are various risk factors that might make someone more likely to abuse drugs.
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States